Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
973.80
+5.80 (+0.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
31
32
Next >
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
July 11, 2023
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look.
Via
InvestorPlace
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
July 11, 2023
Via
Benzinga
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
July 07, 2023
Via
Benzinga
Is Regeneron Stock a Buy After a Regulatory Blow?
July 07, 2023
Don't write this company's eulogy too fast.
Via
The Motley Fool
Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
July 06, 2023
Morgan Stanley cut the price target for ArcBest Corporation (NASDAQ: ARCB) from $136 to $125. Morgan Stanley analyst Ravi Shanker maintained an Overweight rating. ArcBest shares fell 3.3% to close at...
Via
Benzinga
Check Out What Whales Are Doing With REGN
July 03, 2023
Via
Benzinga
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
July 03, 2023
Via
Benzinga
Why Regeneron Pharmaceuticals Stock Dipped This Week
June 29, 2023
A key regulatory setback is weighing on the biotech's stock.
Via
The Motley Fool
Check Out What Whales Are Doing With REGN
June 28, 2023
Via
Benzinga
Is Regeneron's Stock in Trouble After This FDA Rejection?
July 06, 2023
The company's growth rate has been slowing sharply in recent quarters, and Eylea generates the bulk of its product revenue.
Via
The Motley Fool
Biotech Blues: Stay Balanced Through July Earnings Season
July 05, 2023
Life Science stocks lack momentum so be prepared for rebalancing and rotation shifts.
Via
Talk Markets
The 3 Best Biotech Stocks to Buy In July
July 05, 2023
With these companies fueling sales and earnings with medical innovations and breakthroughs, they may be the best biotech stocks to pick up.
Via
InvestorPlace
Stock Market Rally Roars Back Toward Highs; Carnival, Delta, Micron, Nvidia In Focus: Weekly Review
June 30, 2023
Major indexes rebounded strongly and many stocks flashed buy signals.
Via
Investor's Business Daily
What Will Amgen Buy Next?
June 29, 2023
The biotech could pursue these two budget-friendly targets.
Via
The Motley Fool
Where Regeneron Pharmaceuticals Stands With Analysts
June 27, 2023
Via
Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
June 22, 2023
Via
Benzinga
18 Analysts Have This to Say About Regeneron Pharmaceuticals
June 09, 2023
Via
Benzinga
Why Catalent Stock Flopped Today
June 28, 2023
The company takes the fall for a failed drug application.
Via
The Motley Fool
Why Regeneron Stock Is Trading Lower Today
June 28, 2023
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares continue to fall Wednesday after news Tuesday that the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023
June 28, 2023
Via
Benzinga
Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday
June 28, 2023
Deutsche Bank cut the price target for Walgreens Boots Alliance, Inc. (NASDAQ: WBA) from $46 to $34. Deutsche Bank analyst George Hill downgraded the stock from Buy to Hold. Walgreens shares fell 0.2%...
Via
Benzinga
Why Regeneron Stock Is Falling Today
June 27, 2023
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares fell after the FDA issued a Complete Response Letter (CRL) for aflibercept 8 mg Biologics License application due to an ongoing review of...
Via
Benzinga
Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender
June 27, 2023
The FDA still needs to review its inspection of a third-party facility, Regeneron said late Tuesday.
Via
Investor's Business Daily
Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead
June 26, 2023
After a huge run-up in stocks since January investors have come to realize that most of the gains have come from the so-called “Magnificent Seven” tech stocks.
Via
Talk Markets
Biotech And Healthcare Stocks Lagging
June 21, 2023
Healthcare is a laggard with XLV down YTD but UNH is still a core position.
Via
Talk Markets
2 Biotech Stocks You Can Buy and Hold for the Next Decade
June 21, 2023
Gilead and Regeneron Pharmaceuticals both had triple-digit percentage growth over the past decade.
Via
The Motley Fool
How to Retire Rich: Biotech Stocks Edition
June 18, 2023
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks.
Via
InvestorPlace
How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities
June 17, 2023
The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...
Via
Talk Markets
EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035
June 14, 2023
JonesResearch has initiated coverage of ophthalmic biopharmaceutical company EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) with a Buy rating and
Via
Benzinga
2 Stocks to Buy No Matter What Happens in June and Beyond
June 14, 2023
A lot could go wrong in the next few months, but investors should largely ignore all that noise.
Via
The Motley Fool
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.